NASDAQ: SNDX Syndax Pharmaceuticals Inc 8-K

Syndax shareholders approve 7.2M-share equity plan, elect directors at annual meeting

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

  • medium

    Stockholders approved new 2026 Equity Incentive Plan reserving 7.2 million shares for employee grants, replacing expired 2015 plan. Represents potential dilution as awards vest over time.

    Item 5.07: Annual Meeting verify on EDGAR →
  • medium

    Director Pierre Legault re-elected despite 36% withhold vote (21.5M withheld vs 37.3M for), while Michael Metzger received 99% support. Significant opposition to Legault may signal governance concerns.

    Item 5.07: Proposal 1 verify on EDGAR →
  • medium

    New equity plan passed narrowly with 57% approval (33.3M for vs 25.4M against), indicating shareholder concern about dilution from additional equity compensation.

    Item 5.07: Proposal 4 verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade SNDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 10, 2026 9:10 PM